Cardiogenic Shock, Clinical Trial
Official title:
The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score >25)
| Verified date | November 2013 |
| Source | National Taiwan University Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Taiwan: Department of Health |
| Study type | Observational |
The study is to show the prognostic factor of HRV parameter and cardiac fibrosis markers in critical illness patients
| Status | Completed |
| Enrollment | 106 |
| Est. completion date | December 2009 |
| Est. primary completion date | May 2009 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - critical illness patients who are with cardiogenic shock, with ECMO or IABP support, or with APACH II score >25) Exclusion Criteria: - pacemaker rhythm, not sign the permit |
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Country | Name | City | State |
|---|---|---|---|
| Taiwan | National Taiwan University Hospital | Taipei |
| Lead Sponsor | Collaborator |
|---|---|
| National Taiwan University Hospital |
Taiwan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Heart Rate Variability and serum cardiac fibrosis markers in critical illness patients | Outcome measurement: The measure is a composite outcome measure consisting of multiple measures (results to be reported as a single value for each Arm/Group), no changes are required List the primary condition or disease being studied Shock needing ECMO support |
2-4weeks | No |